NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

CareDx, Inc. (CDNA) Stock Analysis

CareDx, Inc. (CDNA) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

CDNA

$50.88

+$1.02 (+2.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CDNA with… →

CDNA Key Statistics

As of Sep 4, 2026
Trading
Open
$49.65
Previous Close
$49.86
Day's Range
48.68–50.99
52-Week Range
13.12–53.67
Volume
1.31M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.43
Valuation
Market Cap
$2.63B
P/E Ratio
24.00
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
38.30
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.75
EPS (ttm)Profit attributable to each share over the last twelve months.
2.12
Financials (FY)
Revenue (FY)
$379.81M+13.79%
Net Income (FY)
−$21.35M−140.64%
Profit marginThe share of revenue left as profit after all costs and taxes.
24.23%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.73M
1-Year Return
+288.40%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CDNA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+170.06%
2025−12.00%
2024+78.42%
2023+5.17%
2022−74.91%
2021−37.23%
2020+235.88%
2019−14.20%
2018+242.51%
2017+171.85%
2016 (partial year)−41.32%

As of September 4, 2026.

CDNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$379.81M−$21.35M−5.6%
2024$333.79M$52.55M15.7%
2023$280.32M−$190.28M−67.9%
2022$321.79M−$76.61M−23.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$379.81M$256.57M−$25.07M−$21.35M−5.6%
2024$333.79M$224.09M−$55.54M$52.55M15.7%
2023$280.32M$178.26M−$107.06M−$190.28M−67.9%
2022$321.79M$209.58M−$77.23M−$76.61M−23.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CDNA Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricCDNADiagnostics & Research medianvs median
P/E24.0033.0827% below
P/S ratio5.754.9915% above
Profit margin24.23%0.00%24.2 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CareDx, Inc. (CDNA) is capitalised at $2.63B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 761.

The 52-week range on file runs from $13.12 to $53.67. CDNA last closed at $50.88 on September 4, 2026. That is +$1.02 (+2.05%) against the previous close. The latest close sits 287.8% above that 52-week low.

Financial Health

In fiscal 2025, CareDx, Inc. reported revenue of $379.81M. That is +13.79% against the prior fiscal year, when revenue was $333.79M. The same year closed with a net loss of $21.35M. The reported profit margin is 24.23%. That is 24.2 percentage points above the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to 2.12.

Across the 4 fiscal years on file, revenue moves from $321.79M in 2022 to $379.81M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 24 times earnings. That is 27.45% below the Diagnostics & Research median of 33.08. The forward P/E on file is 38.3. Measured against sales, the shares trade at 5.75 times revenue. On price-to-sales that is 15.15% above the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the price has returned +288.40%. Measured over 10 years, that is +27.34% a year compounded. Beta against the wider market is reported at 2.43. Annualized volatility over the trailing 10 years is 79.08%.

Growth & Income

No dividend is on file for CDNA.

The strongest complete calendar year on file is 2018 at +242.51%; the weakest is 2022 at −74.91%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is +170.06%.

Peer Comparison

CareDx, Inc. (CDNA) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CareDx, Inc. CDNA $2.63B 24.0
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. CareDx, Inc. trades at a P/E of 24.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CareDx, Inc.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Visit website →